Brazil | Vaccine | 7th July 2021 | Virtual Wire
The Brazilian Health Regulatory Agency (Anvisa) said last Tuesday it has approved the clinical trial of a new COVID-19 vaccine candidate to be developed and tested by Sanofi Pasteur, the vaccination division of French pharmaceutical giant Sanofi.
The clinical study will be phase 1 and 2, Anvisa said, adding that 150 volunteers in Brazil will be used. Vaccine candidates typically must go on to prove their efficacy and safety in phase 3 trials involving thousands of people before manufacturers can receive permission for wider use.
According to Anvisa, the volunteers will receive two doses, 21 days apart, in the states of Bahia, Minas Gerais, Mato Grosso do Sul and Rio de Janeiro.
Even though the rise in Brazil’s COVID-19 case count and the death toll is slowing, the country is still far behind others in getting its population vaccinated. In the past 24 hours, the country registered 62,504 new cases and 780 new deaths. This brings the total in Brazil to nearly 19 million cases and 526,892 deaths.
Follow the Tag on Linkedin